Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-β and Src in tumor growth

Translational Oncology

Volumn 6, Issue 2, 2013, Pages 158-168

  Dickerson, Erin B ^a,b   Marley, Kevin ^c   Edris, Wade ^d   Tyner, Jeffrey W ^e   Schalk, Vidya ^c   MacDonald, Valerie ^f   Loriaux, Marc ^e   Druker, Brian J ^e,g   Helfand, Stuart C ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DOXORUBICIN; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SMALL INTERFERING RNA;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG EFFICACY; GENE SEQUENCE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; ONCOGENE SRC; PROTEIN PHOSPHORYLATION; TUMOR VOLUME;

EID: 84875794442     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12307     Document Type: Article

References (56)

1. Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, and Helman LJ (1998). Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 76, 223-227.
2. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, and van der Graaf WT (2009). The insulin-like growth factor system and sarcomas. J Pathol 217, 469-482.
3. Roholl PJ, Skottner A, Prinsen I, Lips CJ, Den Otter W, and Van Unnik JA (1990). Expression of insulin-like growth factor 1 in sarcomas. Histopathology 16, 455-460.
4. Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, and Haura EB (2012). Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-2511.
5. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, and Bar-Eli M (2002). Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8, 3584-3591.
6. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, and Fletcher JA (2000). KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156, 791-795.
7. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61, 8118-8121.
8. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, and Comoglio PM (1995). The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-749.
9. Ferracini R, Olivero M, Di Renzo MF, Martano M, De Giovanni C, Nanni P, Basso G, Scotlandi K, Lollini PL, and Comoglio PM (1996). Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12, 1697-1705.
10. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, and Tsuneyoshi M (2000). Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 31, 185-192.
11. Fisher C (2010). Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. Virchows Arch 456, 153-166.
12. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580.
13. Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, et al. (2003). C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 21, 1952-1960.
14. Smithey BE, Pappo AS, and Hill DA (2002). C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 26, 486-492.
15. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710.
16. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, et al. (2008). Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26, 620-625.
17. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al. (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26, 626-632.
18. McLeanGW, Carragher NO, Avizienyte E, Evans J, Brunton VG, and FrameMC (2005). The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 5, 505-515.
19. Parsons JT and Parsons SJ (1997). Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 9, 187-192.
20. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, and Parsons SJ (1999). c-Srcmediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274, 8335-8343.
21. Ishizawar R and Parsons SJ (2004). c-Src and cooperating partners in human cancer. Cancer Cell 6, 209-214.
22. Akhtar N, Padilla ML, Dickerson EB, Steinberg H, Breen M, Auerbach R, and Helfand SC (2004). Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 6, 106-116.
23. Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, Padilla M, Frazer-Abel AA, Akhtar N, Getzy DM, et al. (2004). Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 84, 562-572.
24. Koch M, Nielsen GP, and Yoon SS (2008). Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol 97, 321-329.
25. Vail DM and MacEwen EG (2000). Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18, 781-792.
26. Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, and MacEwen EG (2006). Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci 81, 76-86.
27. Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, and Modiano JF (2009). Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One 4, e5549.
28. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, et al. (2006). Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65-75.
29. O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, et al. (2008). SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 105, 5507-5512.
30. Kodama A, Sakai H, Matsuura S, Murakami M, Murai A, Mori T, Maruo K, Kimura T, Masegi T, and Yanai T (2009). Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes. BMC Cancer 9, 363.
31. Heldin CH and Westermark B (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79, 1283-1316.
32. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063.
33. Davis L, Hofmann N, Li G, Huang E, Loriaux M, Bracha S, Helfand S, Mata J, Marley K, Mansoor A, et al. (2013). A case study of personalized therapy for osteosarcoma. Pediatr Blood Cancer.
34. Group TGSTM-A (2010). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28, 1247-1253.
35. Clark MA, Fisher C, Judson I, and Thomas JM (2005). Soft-tissue sarcomas in adults. N Engl J Med 353, 701-711.
36. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU III, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, et al. (2010). Soft tissue sarcoma. J Natl Compr Canc Netw 8, 630-674.
37. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
38. Hansen K and Khanna C (2004). Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 40, 858-880.
39. Paoloni M and Khanna C (2008). Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8, 147-156.
40. Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, Newman RA, Cutter GR, Lindblad-Toh K, Kisseberth WC, Hunter LE, et al. (2011). Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 49, 356-367.
41. Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR, et al. (2010). Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer 10, 619.
42. Hellstrom M, Kalen M, Lindahl P, Abramsson A, and Betsholtz C (1999). Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126, 3047-3055.
43. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, and Lydon NB (2000). Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295, 139-145.
44. Abramsson A, Lindblom P, and Betsholtz C (2003). Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112, 1142-1151.
45. Furuhashi M, Sjoblom T, Abramsson A, Ellingsen J, Micke P, Li H, Bergsten-Folestad E, Eriksson U, Heuchel R, Betsholtz C, et al. (2004). Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 64, 2725-2733.
46. Bergers G, Song S, Meyer-Morse N, Bergsland E, and HanahanD(2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111, 1287-1295.
47. Marley K, Maier CS, and Helfand SC (2012). Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma. Vet Comp Oncol 10, 214-222.
48. Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, et al. (2008). Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 22, 985-988.
49. London CA (2009). Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 24, 106-112.
50. Ishizuka M, Nagai S, Sakamoto KQ, and Fujita S (2007). Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. Xenobiotica 37, 503-513.
51. Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, et al. (2007). Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 35, 1510-1521.
52. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. (2004). Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47, 6658-6661.
53. Fu YN, Yeh CL, Cheng HH, Yang CH, Tsai SF, Huang SF, and Chen YR (2008). EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene 27, 957-965.
54. Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, et al. (2008). Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 14, 4284-4291.
55. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, and Kurie JM (2007). SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170, 366-376.
56. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, and Harari PM (2009). Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8, 696-703.